WAVE Life Sciences

WVE · NASDAQ

$3.42+$0.25 (+7.89%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $3.17

WVE analyst rating

BuyConsensus of 17 analysts over the last 12 months. 94% rate it a buy.

Strong buy0
Buy16
Hold1
Underperform0
Sell0

12-month price target · 18 analysts

Average $19.86 (+480.7% upside)

Low: $12.12
Now: $3.42
High: $44.10

Upgrades and downgrades

The latest rating actions, newest first

WVE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
William Blair	Oct 16, 2026	Initiates	Outperform	—	52%
UBS	Oct 15, 2026	Initiates	Buy	$11.00	69%
Ladenburg Thalmann	Oct 1, 2026	Initiates	Buy	$10.00	13%
JP Morgan	Sep 23, 2026	Downgrade	Overweight → Neutral	—	44%
Mizuho	Aug 4, 2026	Maintains	Outperform	$27.00 → $23.00	40%
Citigroup	Jul 31, 2026	Maintains	Buy	$24.00 → $19.00	36%
B. Riley Securities	Jul 31, 2026	Maintains	Buy	$31.00 → $22.00	30%
Wedbush	Jul 31, 2026	Maintains	Outperform	$15.00 → $12.00	40%
Wells Fargo	May 20, 2026	Maintains	Overweight	$13.00 → $14.00	29%
HC Wainwright & Co.	May 19, 2026	Maintains	Buy	$18.00 → $13.00	54%

The case for and against

Updated Oct 14, 2026

Bull case

Wave Life Sciences is supported by a differentiated RNA-medicines platform, PRISM, which combines RNA editing, antisense silencing, and RNA interference to target both rare and prevalent diseases such as alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease. Its ATS readout showed meaningful biology, including subcutaneous monthly dosing, Z-AAT reductions of 67.7%–70.5%, and a statistically significant CRP correlation of r=0.73 with p<0.001 in n=19, suggesting credible disease-modifying potential. Even though competitors have set a higher functional-AAT bar and BEAM-302 holds a 12–18 month regulatory lead, the expected mid-2026 FDA accelerated-approval feedback remains a key catalyst that could validate Wave’s differentiation and sharpen its commercial path.

Bear case

Wave Life Sciences is viewed negatively because its recent ATS 2026 WVE-006 readout appears clinically and commercially inferior to key competitors, with total AAT levels of 13.6 µM at 400mg and 11.9 µM at 200mg lagging BEAM-302 and Sanofi’s efdoralprin, while also showing a saturating dose-response and an M-AAT% ceiling of 64%. The analysis also highlights an unclear regulatory path, since the company’s composite biomarker package remains unvalidated as a surrogate, and FDA may be reluctant to credit lower total AAT levels as meaningful clinical benefit. More broadly, the stock carries elevated execution, regulatory, and commercial risk across WVE-007, WVE-006, WVE-003, and WVE-N531, with reduced probability-of-success and penetration assumptions contributing to a lower valuation framework.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.